XPH News and Press, SPDR S&P Pharmaceuticals From 01/20/21

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. PTH: a growth ETF in healthcare. For further details see: Healthcare Review Starting In 2021 And Focus On PTH

Click here to read the previous biotech outlook. Investors looking at long-term developmental plays with a significant medical impact are well aware of the biotech investment proposal. After a year centered on addressing challenges related to the global COVID-19 pandemic...

SPDR S&P Pharmaceuticals ETF (XPH) - $0.0538.30-Day SEC Yield of 0.44% as of Dec. 18.Payable Dec 24; for shareholders of record Dec 22; ex-div Dec 21. For further details see: SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.0538

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. For further details see: XLV: Healthcare Dashboard For November

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. For further details see: Healthcare: XLV Survey For October

SPDR S&P Pharmaceuticals ETF (XPH) - $0.0523.30-Day SEC Yield of 0.42% as of Sept. 18.Payable Sep 24; for shareholders of record Sep 22; ex-div Sep 21. For further details see: SPDR S&P Pharmaceuticals ETF declares quarterly distribution of $0.0523

This article series shows every month a dashboard with aggregate industry metrics in healthcare. Most of the companies used to calculate these metrics are holdings of the Health Care Select Sector SPDR ETF ( XLV ). Therefore, this is also a top-down survey of XLV. Shortcut If you are use...

This article series shows every month a dashboard with aggregate industry metrics in healthcare (popular ETFs in this sector: XLV , IYH , IBB , XBI , VHT , XPH ). Shortcut If you are used to this dashboard series or if you are short on time, you can skip the first paragraphs and go...

Patients need access to medicine to treat or manage serious health conditions, no matter what state the economy is in. Drugs are effectively a recession-proof business. As a result, most pharmaceutical stocks have proven steady and some have even thrived, amid the economic crisis caused by the C...

As coronavirus cases continue to soar, the U.S. is in desperate need of a vaccine. Who will get there first? Here are four candidates to consider: AstraZeneca (AZN), Novavax (NVAX), Pfizer (PFE), and Moderna (MRNA). COVID-19 cases continue to rise in the United States and doctors and health...